AAC Accepted Manuscript Posted Online 17 August 2020
Antimicrob. Agents Chemother. doi:10.1128/AAC.00363-20
Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

1 # Rifabutin is bactericidal against intracellular and extracellular forms
2 # of *Mycobacterium abscessus*

3
4
5 **Matt D. Johansen[1], Wassim Daher[1,2], Françoise Roquet-Banères[1], Clément Raynaud[1],**
6 **Matthéo Alcaraz[1], Florian P. Maurer[3,4], and Laurent Kremer[1,2,#]**
7
8
9 [1]Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de
10 Montpellier (IRIM), Université de Montpellier, 1919 route de Mende, 34293, Montpellier, France.
11 [2]INSERM, IRIM, 34293 Montpellier, France.
12 [3]National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel-
13 Leibniz Lung Center, 23845 Borstel, Germany.
14 [4]Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-
15 Eppendorf, Hamburg, Germany
16
17
18
19 [#]To whom correspondence should be addressed:
20 Tel: (+33) 4 34 35 94 47; E-mail: laurent.kremer@irim.cnrs.fr
21
22
23
24 **Running title:** *In vivo* efficacy of rifabutin against *M. abscessus*
25
26
27 **Keywords:** *Mycobacterium abscessus*, rifabutin, macrophage, zebrafish, therapeutic activity.
28

Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy

29 **ABSTRACT**

30

31 *Mycobacterium abscessus* is increasingly recognized as an emerging opportunistic pathogen causing
32 severe lung diseases. As it is intrinsically resistant to most conventional antibiotics, there is an unmet
33 medical need for effective treatments. Repurposing of clinically validated pharmaceuticals represents
34 an attractive option for the development of chemotherapeutic alternatives against *M. abscessus*
35 infections. In this context, rifabutin (RFB) has been shown to be active against *M. abscessus* and has
36 raised renewed interest in using rifamycins for the treatment of *M. abscessus* pulmonary diseases.
37 Herein, we compared the *in vitro* and *in vivo* activity of RFB against the smooth and rough variants of
38 *M. abscessus*, differing in their susceptibility profile to several drugs and physiopathologial
39 characteristics. While the activity of RFB is greater against rough strains than in smooth strains *in*
40 *vitro*, suggesting a role of the glycopeptidolipid layer in susceptibility to RFB, both variants were
41 equally susceptible to RFB inside human macrophages. RFB treatment also led to a reduction in the
42 number and size of intracellular and extracelluar mycobacterial cords. Furthermore, RFB was highly
43 effective in a zebrafish model of infection and protected the infected larvae from *M. abscessus*-
44 induced killing. This was corroborated with a significant reduction in the overall bacterial burden, as
45 well as decreased numbers of abscesses and cords, two major pathophysiological traits in infected
46 zebrafish. This study indicates that RFB is active against *M. abscessus* both *in vitro* and *in vivo,* further
47 supporting its potential usefulness as part of combination regimens targeting this difficult-to-treat
48 mycobacterium.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

INTRODUCTION

Nontuberculous mycobacteria (NTM) are environmental mycobacteria. Among all NTM, *Mycobacterium avium* and *Mycobacterium abscessus* represent the most frequent pathogens associated with pulmonary disease (1). *M. abscessus* is a rapidly growing NTM of increasing clinical significance, particularly in cystic fibrosis (CF) patients (2). In CF patients, infection with *M. abscessus* correlates with a more rapid decline in lung function and can represent an obstacle to subsequent lung transplantation (3–5). From a taxonomical view, the species currently comprises three subspecies: *M. abscessus* subsp. *abscessus* (designated hereafter *M. abscessus)*, *M. abscessus* subsp. *bolletii* (designated hereafter *M. bolletii)* and *M. abscessus* subsp. *massiliense* (designated hereafter *M. massiliense*) (6). These subspecies exhibit different clinical outcomes and drug susceptible profiles to antibiotic treatments (7).

M. abscessus strains can exhibit either a smooth (S) or rough (R) morphotype as a consequence of the presence or absence, respectively, of bacterial surface glycopeptidolipids (GPL) (1, 8–10). These morphological distinctions are associated with important physiological differences. S variants are more hydrophilic than R variants, enabling increased sliding motility and the capacity to form biofilms (8, 9, 11), while the aggregative R variants possess a high propensity to produce large bacterial cords (11, 12). While S and R variants can be viewed as two representatives of the same isolate, which can co-exist and evolve differently in response to host immunity, they express different pathophysiological traits (10). S variants are typically less virulent than the R variants (11, 13, 14), the latter being more frequently associated with severe lung diseases and persisting for years in CF patients (3, 5). Importantly, an S-to-R transition within the colonized host (5, 15) is linked to genetic polymorphisms within the GPL biosynthetic/transport locus (15, 16). Moreover, differences in the susceptibility to drug candidates have been identified between S and R variants (17, 18), highlighting the need for the improved evaluation of new compounds/drug regimens against both morphotypes.

Treatment of *M. abscessus* lung disease remains particularly challenging, largely due to intrinsic resistance to wide panel of antimicrobial agents, including most antitubercular drugs such as rifampicin (RIF) (19–22). The extensive resistome of *M. abscessus* results from a low permeability of the cell wall, absence of drug-activating systems, induction of efflux pumps and production of a wide panel of drug-modifying enzymes (19, 22, 23). In addition, mutations in genes encoding drug targets

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

79 can result in acquired drug resistance further complicating therapy (1, 24). Treatment of infections
80 caused by *M. abscessus* require prolonged courses of multiple antibiotics, usually combining a
81 macrolide (azithromycin or clarithomycin), a β-lactam (imipenem or cefoxitin) and an aminoglycoside
82 (amikacin) (25, 26, 27). Additional drugs, such as tigecycline or clofazimine, are often added to
83 strengthen the regimen, particularly in response to toxic side effects or unsatisfactory clinical
84 response (28). Despite intensive chemotherapy, treatment success rates typically remain around 25-
85 40% in the case of macrolide resistance, which occurs in at least 40-60% of clinical isolates (29).
86 Therefore, there is an urgent clinical need for new drug regimens with improved efficacy (30). While
87 the current drug pipeline against *M. abscessus* remains poor, it has recently been fueled with the
88 discovery of several active hits and the development of repurposed drugs (24). Among the latter,
89 screening of libraries of approved pharmaceuticals revealed that rifabutin (RFB), a rifamycin related
90 to the poorly active rifampicin (RIF), shows activity against *M. abscessus* (31, 32). RIF, along with
91 many other rifamycins, is inactivated by the ADP-ribosyltransferase (Arr_{Mab}) encoded by *MAB_0591*,
92 which ribosylates the drug at the C23 hydroxyl position (33). RFB has also been reported to be as
93 active as clarithromycin in immune-compromized NOD/SCID mice infected with *M. abscessus* (34).
94 However, most studies on RFB have been carried out on either S or R variants (when reported),
95 rendering results sometimes difficult to interpret and/or to compare. Due to the co-existence of S
96 and R variants in patients (15) and the presence of each variant in different compartments (S residing
97 mostly in macrophages and R growing also in the form of intra- or extracellular cords), it is essential
98 to address the activity of RFB on isogenic S/R pairs in both *in vitro* and *in vivo* studies.

99 The present study aimed to describe and compare the activity of RFB against S and R *M.*
100 *abscessus* complex strains *in vitro* and *ex vivo* in a macrophage infection model. Due to the
101 importance of cording, considered as a marker of severity of the infection with the R variant, we also
102 investigated the efficacy of RFB in a zebrafish model of infection.

Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy
Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

103 **MATERIALS AND METHODS**

104

105 **Mycobacterial strains and growth conditions.** *M. abscessus* CIP104536^T, *M. bolletii* CIP108541^T and
106 *M. massiliense* CIP108297^T reference strains and clinical isolates from CF and non-CF patients were
107 reported previously (35, 36). Strains were routinely grown and maintained at 30°C in Middlebrook
108 7H9 broth (BD Difco) supplemented with 0.05% Tween 80 (Sigma-Aldrich) and 10% oleic acid,
109 albumin, dextrose, catalase (OADC enrichment; BD Difco) ($7H9^{T/OADC}$) or on Middlebrook 7H10 agar
110 (BD Difco) containing 10% OADC enrichment ($7H10^{OADC}$) and in the presence of antibiotics, when
111 required. For drug susceptibility testing, bacteria were grown in Cation-Adjusted Mueller-Hinton
112 Broth (CaMHB; Sigma-Aldrich). RFB was purchased from two independent commercial sources
113 (Adooq Bioscience and Selleckchem) and dissolved in DMSO.

114

115 **Drug susceptibility testing.** The minimal inhibitory concentrations (MIC) were determined according
116 to the CLSI guidelines (37). The broth micro-dilution method was used in CaMHB with an inoculum of
117 $5x10^6$ CFU/mL in exponential growth phase. The bacterial suspension was seeded in 100 µL volumes
118 in all of the wells of a 96-well plate, except for the first column, to which 198 µL of the bacterial
119 suspension was added. In the first column, 2 µL of drug at its highest concentration was added to the
120 first well containing 198 µL of bacterial suspension. Two-fold serial dilutions were then carried out
121 and the plates were incubated for 3-5 days at 30°C. MICs were recorded by visual inspection. Assays
122 were completed in triplicate in three independent experiments.

123

124 **Growth inhibition kinetics.** To monitor growth inhibition of *M. abscessus* CIP104536^T S and R, 96-well
125 plates were set-up as for MIC determination and serial dilutions of the bacterial suspensions exposed
126 to increasing concentrations of RFB were plated on LB agar plates after 0, 24, 48 and 72 hrs. Colony-
127 forming units (CFUs) were counted after 4 days of incubation at 30°C. Results from each drug
128 concentration are representative of at least 2 independent experiments.

129

130 **Cytotoxicity assay.** THP-1 cells were differentiated with PMA for 48 hrs and exposed to decreasing
131 concentrations of either RFB or RIF (starting at 200 µg/mL) for an additional 72 hrs at 37°C with 5%
132 CO_2. Following incubation, 10% (vol/vol) resazurin dye was added to each well and left to incubate for

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

133 4 hrs at 37°C and 5% CO_2. Data was acquired using a fluorescent plate reader (excitation 540 nm,
134 emission 590 nm). DMSO was included as a negative control, while SDS was included as a positive
135 control.
136
137 **Intracellular killing assay.** Human THP-1 monocytes were grown in RPMI medium supplemented with
138 10% Fetal bovine serum (Sigma Aldrich) ($RPMI^{FBS}$) and incubated at 37°C in the presence of 5% CO_2.
139 Cells were differentiated into macrophages in the presence of 20 ng/mL Phorbol Myristate Acetate
140 (PMA) in 24-well flat-bottom tissue culture microplates (10^5 cells/mL) and incubated for 48 hrs at
141 37°C with 5% CO_2. Infection with clinical isolates or *M. abscessus* harbouring pTEC27 fluorescent
142 tdTomato was carried out at 37°C in the presence of 5% CO_2 for 3 hrs at a MOI 2:1. After extensive
143 washing with 1X phosphate buffered saline (PBS), cells were incubated with $RPMI^{FBS}$ containing 250
144 µg/mL amikacin for 2 hrs and washed again with PBS prior to the addition of 500 µL $RPMI^{FBS}$
145 containing DMSO (negative control) or 500 µL $RPMI^{FBS}$ containing 50 µg/mL of RIF or AMK, or 12.5
146 µg/mL of RFB. Macrophages were washed with PBS and lysed with 100 µL of 1% Triton X-100 at
147 required time points. Serial dilutions of macrophage lysates were plated onto LB agar plates and
148 colonies were counted to determine intracellular CFUs.
149
150 **Microscopy-based infectivity assays.** Monocytes were differentiated into macrophages (THP-1) in
151 the presence of PMA and were grown on coverslips in 24-well plates at a density of 10^5 cells/mL for
152 48 hrs at 37°C with 5% CO_2 prior to infection with Tdtomato expressing *M. abscessus* for 3 hrs at a
153 MOI of 2:1. After washing and AMK treatment to remove the extracellular bacilli, macrophages were
154 exposed to DMSO (negative control), or 50 µg/mL RIF or AMK, or 12.5 µg/mL RFB, and fixed at 0, 1
155 and 3 days post-infection with 4% paraformaldehyde in PBS for 20 min. Cells were then
156 permeabilized using 0.2% Triton X-100 for 20 min, blocked with 2% BSA in PBS supplemented with
157 0.2% Triton X-100 for 20 min, incubated with anti-CD63 antibodies (Becton Dickinson); dilution
158 1:1000) for 1 hr and with an Alexa Fluor 488-conjugated anti-mouse secondary antibody (Molecular
159 Probes, Invitrogen). After 5 min of incubation with DAPI (dilution 1:1000), cells were mounted onto
160 microscope slides using Immu-mount (Calbiochem) and examined with an epifluorescence
161 microscope using a 63X objective. The average proportion of macrophages containing fewer than <5,
162 5-10, or >10 bacilli were quantified using Zeiss Axio-vision software. Images were acquired by

AAC Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

163 focusing on combined signals (CD63 in green and red fluorescent *M. abscessus*) and captured on a
164 Zeiss Axio-imager confocal microscope equipped with a 63X oil objective and processed using Zeiss
165 Axiovision software. Quantification and scoring of the numbers of bacilli present within macrophages
166 were performed using ImageJ. Equal parameters for the capture and scoring of images were
167 consistently applied to all samples. For each condition, approximately 1000 infected macrophages
168 were analyzed. The presence of the intra- or extracellular cords within or among the macrophages
169 infected with the R morphotype strain were treated in the presence of DMSO, RIF, RFB or AMK at the
170 concentrations previously described, counted and imaged using confocal microscopy.
171
172 **Assessment of RFB efficacy in infected zebrafish.** Experiments in zebrafish were conducted according
173 to the Comité d'Ethique pour l'Expérimentation Animale de la Région Languedoc Roussillon under the
174 reference CEEALR36-1145. Experiments were performed using the *golden* mutant (38). Embryos were
175 obtained and maintained as described (14). Embryo age is expressed as hours post fertilisation (hpf).
176 Red fluorescent *M. abscessus* CIP104536^{T} (R) expressing tdTomato were prepared and microinjected
177 in the caudal vein (2-3 nL containing ≈100 bacteria/nL) in 30 hpf embryos previously dechorionated
178 and anesthetized with tricaine, as described earlier (39). The bacterial inoculum was checked *a*
179 *posteriori* by injection of 2 nL in sterile PBS^{T} and plating on 7H10^{OADC}. Infected embryos were
180 transferred into 24-well plates (2 embryos/well) and incubated at 28.5°C to monitor kinetics of
181 infection and embryo survival. Survival curves were determined by counting dead larvae daily for up
182 to 12 days, with the experiment concluded when uninfected embryos started to die. RFB treatment
183 of infected embryos and uninfected embryos was commenced at 24 hpi (hours post-infection) for 4
184 days. The drug-containing solution was renewed daily. Bacterial loads in live embryos were
185 determined by anesthetising embryos in tricaine as previously described (40), mounting on 3% (w/v)
186 methylcellulose solution and taking fluorescent images using a Zeiss Axio Zoom.V16 coupled with an
187 Axiocam 503 mono (Zeiss). Fluorescence Pixel Count (FPC) measurements were determined using the
188 'Analyse particles' function in ImageJ (39). Bacterial cords were identified based on the size and
189 shape of fluorescent bacteria within the live zebrafish embryo, vastly exceeding the surrounding size
190 and shape of neighbouring cells. All experiments were completed at least three times independently.
191
192

AAC
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

193 **Overexpression of *MAB_1409c* in *M. abscessus*.**
194 Overexpression was achieved by PCR amplification of *MAB_1409c* (*tap)* in fusion with an HA tag using
195 genomic DNA and the forward primer (5′- gagaCAATTGCCATGTCCACTCCGACGGCGGATTC-3′; MfeI)
196 and reverse primer (5′-
197 gagaGTTAACCTAAGCGTAATCTGGAACATCGTATGGGTACCGAGTTGGTTCCTTGTCGGGCT-3′; HpaI). The
198 amplified product was digested with MfeI/HpaI and ligated into the MfeI/HpaI-restricted pMV306
199 integrative vector to generate pMV306-*MAB_1409c*-HA where *MAB_1409c-HA* is under the control of
200 the *hsp60* promoter. The construct was sequenced and electroporated in *M. abscessus* S and R.
201
202 **Selection of resistant *M. abscessus* mutants and target identification.** Exponentially growing *M.*
203 *abscessus* CIP104536^T R cultures were plated on LB agar containing either 25 or 50 µg/mL RFB. After
204 one week of incubation at 37°C, four individual colonies from each RFB concentration were selected,
205 grown in CaMHB, individually assessed for MIC determination and scored for resistance to RFB.
206 Identification of SNPs in the resistant strains was completed by PCR amplification using *rpoB_f* 5'-
207 TCAGTGGGGCTGGTTAG -3' and *rpoB_r* 5'-AAAACATCGCAGATGCGC-3' to produce a 3541 bp amplicon
208 for full coverage sequencing of the *rpoB* gene.
209
210 **Western blotting.** Bacteria were harvested, resuspended in PBS, and disrupted by bead-beating with
211 1-mm diameter glass beads. The protein concentration in the lysates was determined and equal
212 amounts of proteins (100 µg) were subjected to SDS/PAGE. Proteins were transferred to a
213 nitrocellulose membrane. For detection of Tap-HA and KasA (loading control), the membranes were
214 incubated for 1 hr with either the rat anti-HA or rat anti-KasA antibodies (dilution 1:2000), washed,
215 and subsequently incubated with goat anti-rat antibodies conjugated to HRP (Abcam, dilution
216 1:5000). The signal was revealed using the ChemiDoc MP system (Bio-Rad).
217
218 **Statistical analyses.** Statistical analyses were performed on Prism 5.0 (Graphpad) and detailed for
219 each figure legend. *$P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

220 **RESULTS**

221

222 **Rough *M. abscessus* is more susceptible to RFB treatment than smooth *M. abscessus in vitro*.**
223 Exposure of exponentially-growing *M. abscessus* CIP104536[T] S and R isogenic variants to increasing
224 concentrations of RFB, starting at 25 µg/mL for S and 6.25 µg/mL for R, resulted in a noticeable
225 growth inhibition **(Fig. 1)**. At the lowest concentration, the CFUs at 72 hrs post-treatment remained
226 comparable to those of the inoculum, suggestive of a bacteriostatic effect. However, the highest RFB
227 concentrations for both S (200 µg/mL) and R (50 µg/mL) variants were accompanied by 1.81 and 2.47
228 Log reduction in the CFU counts at 72 hrs post-treatment, respectively **(Fig. 1)**. While similar
229 bactericidal effects of RFB were observed against both variants, this was achieved with lower
230 concentrations of RFB against the R variant relative to the isogenic S variant. Overall, RFB at
231 concentratios of 12.50 µg/mL (For R) resulted in a killing effect comparable to the one of imipenem
232 (IPM) used at the MIC (16 µg/mL), known as an active β-lactam drug against *M. abscessus* (41) **(Fig.
233 1)**.

234 To confirm the differences in the susceptibility to RFB, we determined the MIC of the CIP104536[T]
235 S and R variants in CaMHB. **Table 1** clearly shows that the S strain is 4-fold more resistant than its R
236 counterpart. However, both variants were similarly resistant to other rifamycins (RIF, RPT and RFX), in
237 agreement with previous studies (32, 34). Our MIC values, obtained in repetitive experiments with
238 two different commercial sources of RFB, were higher than those reported earlier (32, 34), but
239 comparable to values reported in another study (42). Consistently with other studies (31), we also
240 noticed that the MIC values were dependent on the culture medium **(Table S1)**. Interestingly, MICs of
241 RFB against S and R strains were lower in Middlebrook 7H9 as compared to CaMHB but this effect
242 was lost when supplementing the medium with OADC enrichment. In contrast the S and R strains
243 displayed equal susceptibility levels to RFB in Sauton's medium.

244 To investigate the relationship between RFB activity and GPL production, drug susceptibility was
245 assessed in CaMHB using the GPL-deficient Δ*mmpL4b* mutant, generated in the S background of the
246 type strain CIP104536[T], and its complemented counterpart (14, 43, 44). The *mmpL4b* gene encodes
247 the MmpL4b transporter which participates in the translocation of GPL across the inner membrane
248 (43, 45). Mutations in this gene are associated with loss of GPL and acquisition of a R morphotype

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

249 (13, 43). The parental S strain and, to a lesser extent the Δ*mmpL4b*-complemented strain, showed
250 reduced susceptibility to RFB (MIC 32-64 µg/mL) than the *M. abscessus* R strain and the GPL-deficient
251 Δ*mmpL4b* mutant (MIC 16 µg/mL) **(Table 1)**. The MIC results are in agreement with the growth
252 inhibition kinetics **(Fig. 1)** and suggest that the outer GPL layer influences the activity of RFB.
253 *M. abscessus* possesses numerous potential drug efflux systems (45), including MAB_1409c, a
254 homolog of Rv1258c, previouly reported to mediate efflux of RIF in *M. tuberculosis* (46). We thus
255 addressed whether overexpression of MAB_1409c induces resistance to RFB in *M. abscessus*.
256 *MAB_1409c* was cloned in frame with a HA-tag in the integrative pMV306. The resulting construct
257 pMV306-*MAB_1409c*-HA was introduced in both S and R variants and the expression of MAB_1409c
258 was confirmed by Western blot analysis using anti-HA antibodies **(Fig. S1)**. Drug susceptibility
259 assessment indicated a 4-fold upshift in the MIC of RFB against the R strain carrying pMV306-
260 *MAB_1409c*-HA while no changes in the MIC were observed with the S strain overproducing
261 MAB_1409c **(Table 1)**. This suggests that increasing expression of MAB_1409c in the R variant is likely
262 to mediate efflux of RFB, leading to reduced susceptibility to the drug.
263

264 **RFB is active against S and R *M. abscessus* isolates *in vitro*.** The activity of RFB was next tested using
265 a set of clinical strains isolated from CF patients or non-CF patients. In general, the MIC of R strains
266 were 2 to 4 times lower than those of S strains, altough there were variations among the strains
267 **(Table 2)**. Some R strains (10, 112, 179, 210) exhibited higher MIC values (100 µg/mL) than the
268 reference CIP104536^{T} R strain, while one S strain appeared particularly susceptible to RFB (*M.*
269 *massiliense* 120 with a MIC of 6.25 µg/mL). These differences between strains and S/R morphotypes
270 were not observed previously with BDQ and S and R variants were also equally sensitive to BDQ (47).
271 Overall, these results demonstrate that RFB is active against *M. abscessus*, including isolates from CF
272 patients, while R variants appear in general more susceptible to RFB than S variants, supporting
273 previous findings (48).
274

275 **Mutations in *rpoB* confer resistance to RFB.** Although rifamycin resistance mechanisms mediated by
276 mutations in the *rpoB* gene coding for the β-subunit of RNA polymerase have been widely described
277 for *M. tuberculosis*, this is not the case for *M. abscessus*. Therefore, to identify the mechanism of

Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy
Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

278 resistance of RFB, a genetic approach involving the selection of spontaneous RFB-resistant mutants of
279 *M. abscessus* followed by *rpoB* sequencing was applied. Four spontaneous strains were isolated in
280 the presence of 25 or 50 µg/mL RFB, exhibiting 4- to 8-fold increased resistance levels as compared
281 to the parental strain, respectively **(Table 3)**. Sequencing analyses of *rpoB* identified several single
282 nucleotide polymorphisms (SNPs) across four resistor mutants. In mutants 25.1 and 50.1, a C1339T
283 substitution was identified at position 447 (H447Y). Similarly, in mutant 25.2, a C1339G replacement
284 was found, resulting in an amino acid substitution at position 447 (H447D). Comparatively, in mutant
285 strain 50.2, another SNP (C1355T) occurred, leading to an amino acid change at position 452 (S452L).
286 A comparison of growth of different resistant strains on agar plates containing increasing
287 concentrations of RFB is shown in **Fig. S2**. Whereas RFB abrogated growth of the wild-type S and R
288 strains, growth of all four resistors harbouring mutations at either positions 447 or 452 sustained
289 bacterial growth at 50 µg/mL, confirming that mutations in *rpoB* confer resistance to RFB.
290
291 ***M. abscessus* S and R strains are equally susceptible to RFB in macrophages.** While RFB has been
292 shown to be active against *M. tuberculosis* in a macrophage infection model (49), this has not been
293 thoroughly investigated for *M. abscessus*. We thus compared the intracellular efficacy of RFB in THP-
294 1 macrophages infected with either S or R variants. Firstly, the cytotoxicity of RFB and RIF against
295 THP-1 cells was investigated over a 3-days exposure period to either drug. **Fig. S3**, clearly shows that
296 RFB exerts significant cytotoxicity at concentration >25 µg/ml and that the kinetic of macrophage
297 killing was more rapid with RFB than with RIF. Based on these results, all subsequent macrophage
298 studies were treated with 50 µg/mL RIF or 12.5 µg/mL RFB. AMK at 50 µg/mL was added as a positive
299 control. DMSO-treated macrophages were included as a negative control for intracellular bacterial
300 replication. At 0, 1 and 3 days post-infection (dpi), macrophages were lysed and plated to determine
301 the intracellular bacterial loads following drug treatment. Whereas the presence of DMSO or RIF
302 failed to inhibit intramacrophage growth of *M. abscessus* S, exposure to RFB strongly decreased the
303 intracellular bacterial loads at 1 dpi, with this effect further exacerbated at 3 dpi **(Fig. 2A)**. As
304 anticipated, treatment with RIF did not show any effect, in agreement with the poor activity of this
305 compounds *in vitro* **(Table 1)**. Comparatively, AMK treatment resulted in a significantly reduced
306 intracellular growth rate in both *M. abscessus* S and R variants between 1 and 3dpi. Interestingly, the

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

307 RFB susceptibility profile for the S variant at 1 and 3 dpi was comparable to that of the R variant, with
308 a ~3 Log reduction in the CFU counts **(Fig. 2A and B**, respectively**)**.
309 Macrophages were next infected with *M. abscessus* strains expressing Tdtomato and exposed to
310 either DMSO, AMK, RIF or RFB, followed by staining with anti-CD63 and DAPI and observed under a
311 confocal microscope. A quantitative analysis confirmed the marked reduction in the number of *M.*
312 *abscessus* S-infected THP-1 cells treated with AMK and RFB at 1 and 3 dpi compared to RIF-treated
313 cells or untreated control cells **(Fig. 2C)**. A similar trend was observed when macrophages were
314 infected with *M. abscessus* R **(Fig. 2D)**.
315 Macrophages infected with the S variant were then classified into three categories based on their
316 bacterial burden: poorly infected (<5 bacilli), moderately infected (5-10 bacilli) and heavily infected
317 (>10 bacilli) macrophages. Cells containing bacilli were then individually observed under the
318 microscope and scored to one of the three categories. The quantitative analysis indicates that
319 exposure to RFB significantly reduces the percentage of S variant heavily infected THP-1 cells while
320 increasing the proportion of the poorly infected category, as compared to the untreated cells at 1 dpi
321 **(Fig. 2E)**. At 3 dpi, the effect of RFB was even more pronounced with 10% of the infected bacilli
322 belonging to the heavily infected category and more than 50% associated with the poorly infected
323 category. Analysis performed on cells infected with the R variant generated a similar category profile,
324 although treatment with RFB was associated with a higher proportion of heavily infected
325 macrophages at 3 dpi with the R variant than with the S variant **(Fig. 2F). Fig. 2G** illustrates the
326 reduced number of *M. abscessus* S in infected THP-1 cells treated with RFB at 1 dpi, as compared to
327 the untreated control cells (DMSO) or those treated with RIF or AMK. Collectively, these results
328 indicate that RFB enters THP-1 macrophages and similarly impedes bacterial replication of both *M.*
329 *abscessus* S and R variants.
330
331 **RFB reduces the intramacrophage growth of clinical isolates.** RFB has recently shown vast potential
332 as an effective antibiotic for the treatment of *M. abscessus* infection in a NOD/SCID murine model
333 (34). However, to date the efficacy of RFB has only been evaluated against a limited panel of *M.*
334 *abscessus* clinical isolates within an infection setting. As such, we explored the activity of RFB against
335 S and R clinical isolates of the *M. abscessus* complex with varying MIC values against RFB within THP-
336 1 macrophages. In support of our previous findings in infected macrophages, RFB treatment (12.5 or

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

337 25 μg/mL) was very active against all *M. abscessus* subspecies within macrophages at 1 and 3 dpi
338 when compared to Day 0 and DMSO treatment **(Fig. 3)**, irrespective of S and R morphotypes and the
339 corresponding MIC values **(Table 2)**. Overall, these findings suggest that RFB is very effective against
340 intracellular clinical isolates and highlights the lack of direct correlation between MICs determined *in*
341 *vitro* and the intracellular activity of RFB.
342
343 **Reduced intra- and extracellular cording by RFB treatment.** An important phenotypic difference
344 between S and R morphotypes is that R morphotypes display increased bacterial aggregation. R bacilli
345 remain attached during replication, forming compact colonies containing structures that resemble
346 cords on agar and in broth medium (8, 12, 14). **Fig. 4A** clearly shows that, upon infection with *M.*
347 *abscessus* R expressing TdTomato, the total number of cords per field was significantly reduced in the
348 presence of 50 μg/mL AMK or 12.5 μg/mL RFB when compared to 50 μg/mL RIF or DMSO alone.
349 Moreover, we observed intracellular cords that are capable of growing inside the macrophage as well
350 as in the extracellular milieu, which were easily observable at 3 dpi (**Fig. 4B**). As illustrated in **Fig. 4C**,
351 treatment with AMK or RFB strongly impacted on both intra- and extracellular cords. While AMK
352 treatment severely reduced the number of both intra- and extracellular cords, this effect was almost
353 completely abrogated with RFB at 3 dpi. Together, these results indicate that RFB is highly effective in
354 reducing *M. abscessus* cords, thought to affect the outcome of the infection.
355
356 **RFB treatment enhances protection of zebrafish infected with *M. abscessus*.** *In vivo* drug efficacy
357 has previously been well described using the zebrafish model of infection (40, 47, 50). Initial
358 experiments indicated that RFB concentrations ≤ 100 μg/mL (final concentration in fish water) did not
359 interfere with larval development and was well tolerated in embryos when treatment was applied for
360 4 days with daily drug renewal **(Fig. 5A)**. Higher concentrations of RFB, however, were associated
361 with rapid larval death. As such, only lower RFB doses (≤ 100 μg/mL) were used in subsequent
362 studies. Red fluorescent tdTomato-expressing *M. abscessus* (R variant) was microinjected in the
363 caudal vein of embryos at 30 hrs post-fertilisation (hpf). RFB was directly added at 1 dpi to the water
364 containing the infected embryos, with RFB-supplemented water changed on a daily basis for 4 days.
365 Embryo survival was monitored and recorded daily for 12 days. No decrease in the survival rate was
366 observed in the presence of 5 μg/mL RFB, however, a significant dose-dependent increase in the

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

367 survival of embryos exposed to 25 or 50 µg/mL RFB was observed as compared to the untreated
368 group **(Fig. 5B)**. When exposed to 50 µg/mL RFB, the highest dose examined in this setting, nearly
369 80% of the treated embryos survived at 12 dpi, as compared to 40% of the untreated group. This
370 clearly indicates that RFB protects zebrafish from *M. abscessus* infection.

371 To test whether RFB exerts an effect on the bacterial burden in zebrafish, we quantified
372 fluorescent pixel counts (FPC) (39). As expected, embryos treated with 50 µg/mL RFB had significantly
373 decreased bacterial burdens at 2, 4 and 6 dpi when compared to the untreated group (**Fig. 5C**). These
374 results were corroborated by imaging whole embryos, characterised by the presence of large
375 abscesses and cords in the brain when left untreated and which were observed much less frequently
376 in the RFB-treated animals despite the presence of single bacilli or small aggregated bacteria **(Fig.**
377 **5D)**.

378

379 **RFB treatment reduces abscess formation by *M. abscessus* in zebrafish.** Virulence of *M. abscessus* R
380 variants in zebrafish are correlated with the presence of abscesses, particularly in the central nervous
381 system (14, 39). To address whether the enhanced survival of RFB-treated fish is associated with
382 decreased abscess formation, the percentage of abscesses and cords were determined by monitoring
383 abscesses and cords in whole embryos, as reported previously (14, 39). Extracellular cords can be
384 easily distinguished based on their serpentine-like shape and by their size, often greater as compared
385 to the size of the surrounding macrophages and neutrophils. Exposure of infected embryos to 50
386 µg/mL RFB was accompanied by a significant decrease in the proportion of embryos with cords **(Fig.**
387 **6A)** at 4 dpi, and the number of embryos with abscesses **(Fig. 6B)** at 4 and 6 dpi. This decrease in the
388 physiopathological signs of RFB-treated larvae correlates also with the FPC analysis and whole
389 embryo imaging **(Fig. 6C and 6D)**. Overall, these results demonstrate that RFB reduces the
390 pathophysiology of *M. abscessus* infection in zebrafish larvae and protects them from bacterial
391 killing.

AAC

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

392 **DISCUSSION**

393

394 Treatment success of infections caused by *M. abscessus* is unacceptably low even upon prolonged,
395 multidrug chemotherapy with a significant risk of severe toxic side effects. Although RIF is used as a
396 first-line drug against *M. tuberculosis*, it has no activity against *M. abscessus*. While ADP
397 ribosyltransferases can utilise both RIF and RFB as substrates (51), a lower catalytic efficiency with
398 RFB may explain its greater potency against *M. abscessus*. Our study supports and extends previous
399 investigations highlighting the potential of RFB against *M. abscessus in vitro* against a wide panel of
400 *M. abscessus* complex clinical isolates (31, 32, 52, 53). We found, however, that our MIC values were
401 higher than those observed in previous investigations (31, 32). In our study, following the Clinical and
402 Laboratory Standard Institute (CLSI) guidelines, MIC were determined in CaMHB while Aziz *et al*.
403 showed that MIC values were 2- to 3-fold higher in CaMHB as compared to Middlebrook 7H9 (31),
404 clearly implicating an effect of medium on RFB susceptibility testing. In line with these results, we
405 noticed important variations in the MIC values depending on the culture medium used for RFB
406 susceptibility assessments. It is also noteworthy that the growth curve of the untreated S strain is
407 different from the one of the R strain, which is very likely linked to the highly aggregative surface
408 properties typifying the R strain which, in contrast to the S strain, produces very clumpy and corded
409 cultures in broth medium (10, 39, 54). As a consequence, colonies on agar plates are very likely
410 emerging from aggregated bacteria rather than individual bacilli, explaining why the CFU counts were
411 significantly lower in both cultures. Thus, the CFU counts of the R strain does not accurately reflect
412 the absolute number of living bacilli in the culture. We also selected RFB-resistant mutants and
413 identified mutations in *rpoB,* known as the primary target of rifampicin in *M. tuberculosis* (55).
414 Interestingly, the mutations identified are part of the rifampicin-resistance-determining region
415 (RRDR), a 81-bp central segment corresponding to codons 426 to 452 in *M. tuberculsosis* that
416 harbours the vast majority of *rpoB* mutations associated with resistance to RIF (55). Noteworthingly,
417 S452L corresponds to one of the most frequently mutated coding region in the *rpoB* gene in *M.*
418 *tuberculosis* (S450L replacement) (55). Together, these results suggest RpoB is very likely the target of
419 RFB in *M. abscessus*.

420 Among the various studies reporting the activity of RFB against *M. abscessus in vitro*, very few
421 discriminated the activity of RFB against the S or R morphotypes. Herein, we found that the type

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

422 strain CIP104536^T S was reproducibly more resistant to RFB than its R counterpart. Supporting these
423 results, deletion of *mmpL4b* in the S genetic background, resulting into an R morphotype lacking GPL
424 (13, 43), increased susceptibility to RFB. Conversely, functional complementation of the *mmpL4b*
425 mutant, restoring the S morphotype and GPL production (13, 43), partially rescued the higher MIC.
426 This highlights the influence of the outermost GPL layer on susceptility to RFB. Previously, the activity
427 of other inhibitors have been shown to be dependent on the presence or absence of GPL in *M.*
428 *abscessus* (17, 18). A logical explanation is that the GPL layer protects the bacilli from the penetration
429 of drugs. The absence of GPL may enhance the permeability of the cell wall and accumulation of the
430 drug inside the bacteria. However, one cannot exclude the possibility that MmpL4b, like other MmpL
431 transporters, can act as an efflux pump (56–58) and may participate in the extrusion of RFB in *M.*
432 *abscessus* S, resulting in higher MIC. The implication of efflux pumps in resistance to RFB has been
433 investigated, whereby the overexpression of MAB_1409c (a homologue of the *M. tuberculosis*
434 Rv1258c) resulted in increased resistance to RFB in the R variant of *M. abscessus*. This effect was not
435 observed in the S strain overexpressing MAB_1409c, presumably because of the already elevated
436 MIC of the parental S strain towards RFB. However, while the increased susceptibility of the R strain
437 as compared to the S strain was true with respect to the type strain, this was not observed for all
438 clinical strains tested. The heterogeneity of the clinical strains in response to RFB treatment cannot
439 be simply explained by the presence or absence of GPL, but may also include additional determinants
440 of resistance to RFB (52), such as differences in the expression level of Arr_{Mab} or the expression of Rox
441 monooxygenases, known to inactivate RIF in other bacterial species as proposed earlier (59). This,
442 however, requires further investigation in follow-up studies.

443 One unanticipated finding from this study relies on the fact that, although S and R variants
444 respond differently to RFB treatment *in vitro*, this was not the case against the intracellularly-residing
445 *M. abscessus*. We found that, using a macrophage model of infection, the isogenic S and R type
446 strains responded equally well to treatment with 12.5 µg/mL RFB, largely exceeding the results
447 obtained with AMK, a drug displaying weak intracellular activity (60). These observations are
448 reminiscent of other studies indicating that various naphtalenic ansamycins, including RIF, differ
449 profoundly in their capacity to kill extracellular *Staphylococcus aureus*, albeit there were few
450 differences observed between them in promoting human macrophages to kill phagocytosed bacteria
451 (61). There is no simple explanation as why *M. abscessus* S is as efficiently killed as *M. abscessus* R

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

452 inside the cells. A plausible explanation may be that the stress response inside macrophages alters
453 the composition/architecture of the cell wall of *M. abscessus*, thereby affecting the GPL layer and/or
454 permeability of the S variant. It has been shown that the GPL layer significantly influences the
455 hydrophobic surface properties (62), potentially impacting on the adhesion and the uptake of the
456 bacilli. Furthermore, electron microscopy observations revealed that the electron translucent zone
457 (ETZ) that fills the entire space between the phagosome and the bacterial surface relies on GPL
458 production in the S variant (11). Alternatively, RFB may directly induce the antimycobacterial activity
459 of the macrophage, which in turns translates into a rapid killing of the phagocytosed bacteria,
460 regardless of their morphotype. Overall, these results suggest that the MIC values of RFB are not
461 indicative of the intraphagocytic killing of *M. abscessus* and highlights the importance of testing the
462 efficacy of drugs in a macrophage infection model.

463 Cords and abscesses are pathophysiological markers of *M. abscessus* infection, as revealed using
464 the zebrafish model of infection (40). In particular, extracellular cords, due to their size, prevent the
465 bacilli from being phagocytosed by macrophages and neutrophils, representing an important
466 mechanism of immune evasion (14, 39). We demonstrate here that treatment of infected
467 macrophages was associated with reduced intra- and extracellular cording of the R variant. It is very
468 likely that RFB prevents cording, as a consequence of the inhibition of bacterial replication/killing.
469 Cords are a hallmark of virulence of the R variant of *M. abscessus*, as emphasized by a deletion
470 mutant of *MAB_4780*, encoding a dehydratase, displaying a pronounced defect in cording and a
471 highly attenuated phenotype in macrophages (63). Importantly, we observed also a significant
472 decrease in the number of embryos with cords following RFB treatment in infected zebrafish. It is
473 worth highlighting that in the presence of RFB, there is no change in the number of embryos with
474 cords between 2 and 4 dpi, implying that while RFB does not degrade or modify the bacterial cord
475 structure, it likely prevents the formation of additional cords. Moreover, the effect of RFB on cord
476 reduction is particularly interesting as it may prevent the subsequent formation of abscesses (14),
477 considered as a marker of severity of the disease. Consistent with this hypothesis, a marked decrease
478 in abscess formation was observed in RFB-treated zebrafish embryos. Overall, this work supports the
479 practicality of zebrafish as a pre-clinical model to evaluate in real-time the bactericidal efficacy of RFB
480 against *M. abscessus* infection in the sole context of innate immunity.

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

481 In summary, although there is a clear lack of bactericidal activity of drugs against *M. abscessus*
482 (64), these findings support the high activity of RFB against *M. abscessus in vivo* and *in vitro*. Our
483 results further emphasize the efficacy of RFB against both extracellular and intracellular forms of *M.*
484 *abscessus,* both co-existing in infected patients, as well as a protective effect in an animal model of
485 *M. abscessus* infection. In addition, we have provided further evidence that S and R variants are
486 differentially susceptible to RFB, likely due to the GPL layer, however the MIC values are not
487 predictive of intracellular drug efficacy.

488 Together with the fact that RFB is an FDA-approved drug that is already used to treat
489 tuberculosis (66) and *M. avium* infections (67) with favourable pharmacological properties (68), our
490 data strengthen the view that RFB should be considered as a repurposing drug candidate for the
491 treatment of *M. abscessus* infections. Importantly, recent work has shown that RFB is synergistic in
492 combinations with other antimicrobials such as clarithromycin, imipenem and tigecycline, and
493 significantly improves the activity of imipenem-tedizolid drug combinations (32, 48, 53, 65). Future
494 studies are required to test whether these RFB combinations are effective against *M. abscessus*
495 pulmonary infections.

Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

496 **ACKNOWLEDGMENTS**

497

498 MDJ received a post-doctoral fellowship granted by Labex EpiGenMed, an «Investissements d'avenir»
499 program (ANR-10-LABX-12-01). This study was supported by the Association Gregory Lemarchal and
500 Vaincre la Mucoviscidose (RIF20180502320) to LK.
501 The authors have no conflict of interest to declare.

502

503 **REFERENCES**

504

505 1. Johansen MD, Herrmann J-L, Kremer L. 2020. Non-tuberculous mycobacteria and the rise of
506 *Mycobacterium abscessus*. Nat Rev Microbiol. 18:392-407.

507 2. Cowman S, van Ingen J, Griffith DE, Loebinger MR. 2019. Non-tuberculous mycobacterial
508 pulmonary disease. Eur Respir J 54:1900250.

509 3. Jönsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Olsson C. 2007. Molecular
510 epidemiology of *Mycobacterium abscessus*, with focus on cystic fibrosis. J Clin Microbiol
511 45:1497–1504.

512 4. Esther CR, Esserman DA, Gilligan P, Kerr A, Noone PG. 2010. Chronic *Mycobacterium abscessus*
513 infection and lung function decline in cystic fibrosis. J Cyst Fibros 9:117–123.

514 5. Catherinot E, Roux A-L, Macheras E, Hubert D, Matmar M, Dannhoffer L, Chinet T, Morand P,
515 Poyart C, Heym B, Rottman M, Gaillard J-L, Herrmann J-L. 2009. Acute respiratory failure
516 involving an R variant of *Mycobacterium abscessus*. J Clin Microbiol 47:271–274.

Accepted Manuscript Posted Online

517 6. Adekambi T, Sassi M, van Ingen J, Drancourt M. 2017. Reinstating *Mycobacterium massiliense*
518 and *Mycobacterium bolletii* as species of the *Mycobacterium abscessus* complex. Int J Syst Evol
519 Microbiol 67:2726–2730.

520 7. Koh W-J, Jeon K, Lee NY, Kim B-J, Kook Y-H, Lee S-H, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL,
521 Kwon OJ. 2011. Clinical significance of differentiation of *Mycobacterium massiliense* from
522 *Mycobacterium abscessus.* Am J Respir Crit Care Med 183:405–410.

523 8. Howard ST, Rhoades E, Recht J, Pang X, Alsup A, Kolter R, Lyons CR, Byrd TF. 2006. Spontaneous
524 reversion of *Mycobacterium abscessus* from a smooth to a rough morphotype is associated with
525 reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype.
526 Microbiology (Reading, Engl) 152:1581–1590.

527 9. Gutiérrez AV, Viljoen A, Ghigo E, Herrmann J-L, Kremer L. 2018. Glycopeptidolipids, a double-
528 edged sword of the *Mycobacterium abscessus* complex. Front Microbiol 9:1145.

529 10. Roux A-L, Viljoen A, Bah A, Simeone R, Bernut A, Laencina L, Deramaudt T, Rottman M, Gaillard
530 J-L, Majlessi L, Brosch R, Girard-Misguich F, Vergne I, de Chastellier C, Kremer L, Herrmann J-L.
531 2016. The distinct fate of smooth and rough *Mycobacterium abscessus* variants inside
532 macrophages. Open Biol 6:160185.

533 11. Bernut A, Viljoen A, Dupont C, Sapriel G, Blaise M, Bouchier C, Brosch R, de Chastellier C,
534 Herrmann J-L, Kremer L. 2016. Insights into the smooth-to-rough transitioning in *Mycobacterium*
535 *bolletii* unravels a functional Tyr residue conserved in all mycobacterial MmpL family members.
536 Mol Microbiol 99:866–883.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

537 12. Sánchez-Chardi A, Olivares F, Byrd TF, Julián E, Brambilla C, Luquin M. 2011. Demonstration of
538 cord formation by rough *Mycobacterium abscessus* variants: implications for the clinical
539 microbiology laboratory. J Clin Microbiol 49:2293–2295.

540 13. Nessar R, Reyrat J-M, Davidson LB, Byrd TF. 2011. Deletion of the *mmpL4b* gene in the
541 *Mycobacterium abscessus* glycopeptidolipid biosynthetic pathway results in loss of surface
542 colonization capability, but enhanced ability to replicate in human macrophages and stimulate
543 their innate immune response. Microbiology (Reading, Engl) 157:1187–1195.

544 14. Bernut A, Herrmann J-L, Kissa K, Dubremetz J-F, Gaillard J-L, Lutfalla G, Kremer L. 2014.
545 *Mycobacterium abscessus* cording prevents phagocytosis and promotes abscess formation. Proc
546 Natl Acad Sci USA 111:E943-952.

547 15. Park IK, Hsu AP, Tettelin H, Shallom SJ, Drake SK, Ding L, Wu U-I, Adamo N, Prevots DR, Olivier
548 KN, Holland SM, Sampaio EP, Zelazny AM. 2015. Clonal diversification and changes in lipid traits
549 and colony morphology in *Mycobacterium abscessus* clinical isolates. J Clin Microbiol 53:3438–
550 3447.

551 16. Pawlik A, Garnier G, Orgeur M, Tong P, Lohan A, Le Chevalier F, Sapriel G, Roux A-L, Conlon K,
552 Honoré N, Dillies M-A, Ma L, Bouchier C, Coppée J-Y, Gaillard J-L, Gordon SV, Loftus B, Brosch R,
553 Herrmann JL. 2013. Identification and characterization of the genetic changes responsible for
554 the characteristic smooth-to-rough morphotype alterations of clinically persistent
555 *Mycobacterium abscessus*. Mol Microbiol 90:612–629.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

AAC
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

556 17. Madani A, Ridenour JN, Martin BP, Paudel RR, Abdul Basir A, Le Moigne V, Herrmann J-L,
557 Audebert S, Camoin L, Kremer L, Spilling CD, Canaan S, Cavalier J-F. 2019. Cyclipostins and
558 Cyclophostin analogues as multitarget inhibitors that impair growth of *Mycobacterium*
559 *abscessus*. ACS Infect Dis 5:1597–1608.

560 18. Lavollay M, Dubée V, Heym B, Herrmann J-L, Gaillard J-L, Gutmann L, Arthur M, Mainardi J-L.
561 2014. *In vitro* activity of cefoxitin and imipenem against *Mycobacterium abscessus* complex. Clin
562 Microbiol Infect 20:O297–O300.

563 19. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. 2012. *Mycobacterium abscessus*: a new
564 antibiotic nightmare. J Antimicrob Chemother 67:810–818.

565 20. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. 2012. Resistance mechanisms and drug
566 susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 15:149–161.

567 21. Brown-Elliott BA, Nash KA, Wallace RJ. 2012. Antimicrobial susceptibility testing, drug resistance
568 mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev
569 25:545–582.

570 22. Lopeman R, Harrison J, Desai M, Cox J. 2019. Mycobacterium abscessus: Environmental
571 bacterium turned clinical nightmare. Microorganisms 7:90.

572 23. Luthra S, Rominski A, Sander P. 2018. The role of antibiotic-target-modifying and antibiotic-
573 modifying enzymes in *Mycobacterium abscessus* drug resistance. Front Microbiol 9:2179.

AAC
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

574 24. Wu M-L, Aziz DB, Dartois V, Dick T. 2018. NTM drug discovery: status, gaps and the way forward.
575 Drug Discov Today 23:1502–1519.

576 25. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh
577 R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K,
578 ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease
579 Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention
580 of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416.

581 26. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P,
582 Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J,
583 Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. 2016. US Cystic Fibrosis Foundation and
584 European Cystic Fibrosis Society consensus recommendations for the management of non-
585 tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax 71:88–
586 90.

587 27. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith
588 DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE,
589 Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020. Treatment of nontuberculous
590 mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
591 Eur Respir J 56:2000535.

592 28. Wallace RJ, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. 2014. Clinical
593 experience in 52 patients with tigecycline-containing regimens for salvage treatment of

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

594 *Mycobacterium abscessus* and *Mycobacterium chelonae* infections. J Antimicrob Chemother
595 69:1945–1953.

596 29. Roux A-L, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, Chiron R, Fauroux B, Le
597 Bourgeois M, Munck A, Pin I, Sermet I, Gutierrez C, Véziris N, Jarlier V, Cambau E, Herrmann J-L,
598 Guillemot D, Gaillard J-L, OMA group. 2015. Comparing *Mycobacterium massiliense* and
599 *Mycobacterium abscessus* lung infections in cystic fibrosis patients. J Cyst Fibros 14:63–69.

600 30. Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL,
601 Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL,
602 Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF,
603 Winthrop KL, Zelazny AM. 2019. Advancing translational science for pulmonary nontuberculous
604 mycobacterial infections. A road map for research. Am J Respir Crit Care Med 199:947–951.

605 31. Aziz DB, Low JL, Wu M-L, Gengenbacher M, Teo JWP, Dartois V, Dick T. 2017. Rifabutin is active
606 against *Mycobacterium abscessus* complex. Antimicrob Agents Chemother. 61:e00155-17.

607 32. Pryjma M, Burian J, Thompson CJ. 2018. Rifabutin acts in synergy and is bactericidal with
608 frontline *Mycobacterium abscessus* antibiotics clarithromycin and tigecycline, suggesting a
609 potent treatment combination. Antimicrob Agents Chemother 62:e00283-18.

610 33. Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P. 2017. Intrinsic rifamycin resistance
611 of *Mycobacterium abscessus* is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob
612 Chemother 72:376–384.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

613 34. Dick T, Shin SJ, Koh W-J, Dartois V, Gengenbacher M. 2019. Rifabutin is active against
614 *Mycobacterium abscessus* in mice. Antimicrob Agents Chemother 64:e01943-19.

615 35. Singh S, Bouzinbi N, Chaturvedi V, Godreuil S, Kremer L. 2014. *In vitro* evaluation of a new drug
616 combination against clinical isolates belonging to the *Mycobacterium abscessus* complex. Clin
617 Microbiol Infect 20:O1124-1127.

618 36. Halloum I, Viljoen A, Khanna V, Craig D, Bouchier C, Brosch R, Coxon G, Kremer L. 2017.
619 Resistance to thiacetazone derivatives active against *Mycobacterium abscessus* involves
620 mutations in the MmpL5 transcriptional repressor MAB_4384. Antimicrob Agents Chemother
621 61:e02509-16.

622 37. Woods, GL, Brown-Elliott, BA, Conville, PS, Desmond, EP, Hall, GS, Lin G, Pfyffer GE, Ridderhof,
623 JC, Siddiqi, SH, Wallace, RJ. 2011. Susceptibility testing of mycobacteria, nocardiae and other
624 aerobic actinomycetes: approved standardSecond Edition. M24-A2. Clinical and Laboratory
625 Standards Institute, Wayne, PA 2011.

626 38. Lamason RL, Mohideen M-APK, Mest JR, Wong AC, Norton HL, Aros MC, Jurynec MJ, Mao X,
627 Humphreville VR, Humbert JE, Sinha S, Moore JL, Jagadeeswaran P, Zhao W, Ning G,
628 Makalowska I, McKeigue PM, O'donnell D, Kittles R, Parra EJ, Mangini NJ, Grunwald DJ, Shriver
629 MD, Canfield VA, Cheng KC. 2005. SLC24A5, a putative cation exchanger, affects pigmentation in
630 zebrafish and humans. Science 310:1782–1786.

Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy
Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

631 39. Bernut A, Dupont C, Sahuquet A, Herrmann J-L, Lutfalla G, Kremer L. 2015. Deciphering and
632 imaging pathogenesis and cording of *Mycobacterium abscessus* in zebrafish embryos. J Vis Exp
633 103:e53130.

634 40. Bernut A, Le Moigne V, Lesne T, Lutfalla G, Herrmann J-L, Kremer L. 2014. *In vivo* assessment of
635 drug efficacy against *Mycobacterium abscessus* using the embryonic zebrafish test system.
636 Antimicrob Agents Chemother 58:4054–4063.

637 41. Lefebvre A-L, Dubée V, Cortes M, Dorchêne D, Arthur M, Mainardi J-L. 2016. Bactericidal and
638 intracellular activity of β-lactams against *Mycobacterium abscessus*. J Antimicrob Chemother
639 71:1556–1563.

640 42. Story-Roller E, Maggioncalda EC, Lamichhane G. 2019. Select β-lactam combinations exhibit
641 synergy against *Mycobacterium abscessus in vitro*. Antimicrob Agents Chemother 63:e00614-19.

642 43. Medjahed H, Reyrat J-M. 2009. Construction of *Mycobacterium abscessus* defined
643 glycopeptidolipid mutants: comparison of genetic tools. Appl Environ Microbiol 75:1331–1338.

644 44. Roux A-L, Ray A, Pawlik A, Medjahed H, Etienne G, Rottman M, Catherinot E, Coppée J-Y, Chaoui
645 K, Monsarrat B, Toubert A, Daffé M, Puzo G, Gaillard J-L, Brosch R, Dulphy N, Nigou J, Herrmann
646 J-L. 2011. Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent
647 mycobacterial variants. Cell Microbiol 13:692–704.

648 45. Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, Rottman M, Macheras E, Heym B, Herrmann
649 J-L, Daffé M, Brosch R, Risler J-L, Gaillard J-L. 2009. Non mycobacterial virulence genes in the
650 genome of the emerging pathogen *Mycobacterium abscessus*. PLoS ONE 4:e5660.

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

651 46. Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. 2012. Efflux pumps of
652 *Mycobacterium tuberculosis* play a significant role in antituberculosis activity of potential drug
653 candidates. Antimicrob Agents Chemother 56:2643–2651.

654 47. Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann J-L, Pethe K, Kremer L. 2017.
655 Bedaquiline inhibits the ATP synthase in *Mycobacterium abscessus* and is effective in infected
656 zebrafish. Antimicrob Agents Chemother 61:e01225-17.

657 48. Cheng A, Tsai Y-T, Chang S-Y, Sun H-Y, Wu U-I, Sheng W-H, Chen Y-C, Chang S-C. 2019. *In vitro*
658 synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the
659 *Mycobacterium abscessus* complex. Antimicrob Agents Chemother 63:e02234-18.

660 49. Luna-Herrera J, Reddy MV, Gangadharam PRJ. 1995. *In vitro* and intracellular activity of rifabutin
661 on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J Antimicrob Chemother
662 36:355–363.

663 50. Dubée V, Bernut A, Cortes M, Lesne T, Dorchene D, Lefebvre A-L, Hugonnet J-E, Gutmann L,
664 Mainardi J-L, Herrmann J-L, Gaillard J-L, Kremer L, Arthur M. 2015. β-Lactamase inhibition by
665 avibactam in *Mycobacterium abscessus*. J Antimicrob Chemother 70:1051–1058.

666 51. Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, Zhang K, Junop M, Wright GD. 2008.
667 Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr. Proc Natl
668 Acad Sci USA 105:4886–4891.

669 52. Ganapathy US, Dartois V, Dick T. 2019. Repositioning rifamycins for *Mycobacterium abscessus*
670 lung disease. Expert Opin Drug Discov 1–12.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

AAC
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

671 53. Le Run E, Arthur M, Mainardi J-L. 2018. *In vitro* and intracellular activity of imipenem combined
672 with rifabutin and avibactam against *Mycobacterium abscessus*. Antimicrob Agents Chemother
673 62:e00623-18.

674 54. Brambilla C, Llorens-Fons M, Julián E, Noguera-Ortega E, Tomàs-Martínez C, Pérez-Trujillo M,
675 Byrd TF, Alcaide F, Luquin M. 2016. Mycobacteria clumping increase their capacity to damage
676 macrophages. Front Microbiol 7:1562.

677 55. Jagielski T, Bakuła Z, Brzostek A, Minias A, Stachowiak R, Kalita J, Napiórkowska A,
678 Augustynowicz-Kopeć E, Żaczek A, Vasiliauskiene E, Bielecki J, Dziadek J. 2018. Characterization
679 of mutations conferring resistance to rifampin in *Mycobacterium tuberculosis* clinical strains.
680 Antimicrob Agents Chemother 62:e01093-18.

681 56. Richard M, Gutiérrez AV, Viljoen AJ, Ghigo E, Blaise M, Kremer L. 2018. Mechanistic and
682 structural insights into the unique TetR-dependent regulation of a drug efflux pump in
683 *Mycobacterium abscessus*. Front Microbiol 9:649.

684 57. Richard M, Gutiérrez AV, Viljoen A, Rodriguez-Rincon D, Roquet-Baneres F, Blaise M, Everall I,
685 Parkhill J, Floto RA, Kremer L. 2019. Mutations in the MAB_2299c TetR regulator confer cross-
686 resistance to clofazimine and bedaquiline in *Mycobacterium abscessus*. Antimicrob Agents
687 Chemother 63:e01316-18.

688 58. Gutiérrez AV, Richard M, Roquet-Banères F, Viljoen A, Kremer L. 2019. The TetR-family
689 transcription factor MAB_2299c regulates the expression of two distinct MmpS-MmpL efflux

AAC
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

690 pumps involved in cross-resistance to clofazimine and bedaquiline in *Mycobacterium abscessus*.
691 Antimicrob Agents Chemother. 63:e01000-19.

692 59. Koteva K, Cox G, Kelso JK, Surette MD, Zubyk HL, Ejim L, Stogios P, Savchenko A, Sørensen D,
693 Wright GD. 2018. Rox, a rifamycin resistance enzyme with an unprecedented mechanism of
694 action. Cell Chemical Biology 25:403-412.e5.

695 60. Lefebvre A-L, Le Moigne V, Bernut A, Veckerlé C, Compain F, Herrmann J-L, Kremer L, Arthur M,
696 Mainardi J-L. 2017. Inhibition of the β-lactamase BlaMab by avibactam improves the *in vitro* and
697 *in vivo* efficacy of imipenem against *Mycobacterium abscessus*. Antimicrob Agents Chemother
698 61:e02440-16.

699 61. Marshall VP, Cialdella JI, Ohlmann GM, Gray GD. 1983. MIC values do not predict the
700 intraphagocytic killing of *Staphylococcus aureus* by naphthalenic ansamycins. J Antibiot
701 36:1549–1560.

702 62. Viljoen A, Viela F, Kremer L, Dufrêne YF. 2020. Fast chemical force microscopy demonstrates
703 that glycopeptidolipids define nanodomains of varying hydrophobicity on mycobacteria.
704 Nanoscale Horiz 5:944–953.

705 63. Halloum I, Carrère-Kremer S, Blaise M, Viljoen A, Bernut A, Le Moigne V, Vilchèze C, Guérardel Y,
706 Lutfalla G, Herrmann J-L, Jacobs WR, Kremer L. 2016. Deletion of a dehydratase important for
707 intracellular growth and cording renders rough *Mycobacterium abscessus* avirulent. Proc Natl
708 Acad Sci USA 113:E4228-4237.

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

709 64. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV, Böttger EC. 2014. Lack of
710 antimicrobial bactericidal activity in *Mycobacterium abscessus.* Antimicrob Agents Chemother
711 58:3828–3836.

712 65. Le Run E, Arthur M, Mainardi J-L. 2019. *In vitro* and intracellular activity of imipenem combined
713 with tedizolid, rifabutin, and avibactam against *Mycobacterium abscessus.* Antimicrob Agents
714 Chemother 63:e01915-18.

715 66. Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Koh W-J. 2017. Treatment outcomes
716 of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary
717 tuberculosis. Int J Infect Dis 65:135–141.

718 67. Griffith DE. 2018. Treatment of *Mycobacterium avium* complex (MAC). Semin Respir Crit Care
719 Med 39:351–361.

720 68. Blaschke TF, Skinner MH. 1996. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22
721 Suppl 1:S15-21; discussion S21-22.

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

722 **Table 1.** Drug susceptibility/resistance profile of smooth and rough variants derived from the
723 reference *M. abscessus* 104536^T strain to various rifamycins in CaMBH. MIC (µg/mL) were
724 determined following the CLSI guidelines.

725
726
727
728
729
730
731
732
733
734
735
736

		MIC (µg/mL)			
Strain	**Morphotype**	**RFB**	**RIF**	**RPT**	**RFX**
CIP104536 (S)	S	64	>128	>128	>128
CIP104536 (R)	R	16	>128	>128	>128
ΔMAB_mmpL4b	R	16	>128	>128	>128
ΔMAB_mmpL4b_C	S	32	>128	>128	>128
CIP104536 (S) + pMV306-*MAB_1409c-HA*	S	64	>128	>128	>128
CIP104536 (R) + pMV306-*MAB_1409c-HA*	R	64	>128	>128	>128

RFB, Rifabutin; RIF, rifampicin; RPT, rifapentine; RFX, rifaximin.

Accepted Manuscript Posted Online
AAC
Antimicrobial Agents and Chemotherapy

737 **Table 2. Comparison of the activity of RFB against clinical isolates from CF and non-CF patients.** The
738 MIC (µg/mL) was determined in Cation-Adjusted Mueller-Hinton broth for different subspecies
739 belonging to the *M. abscessus* complex. Results are from 3 independent experiments. RFB, rifabutin.
740
741
742
743
744
745
746

Strain	Morphotype	Source	RFB
M. abscessus			
CIP104536	S	Non-CF	50
3321	S	Non-CF	50
1298	S	CF	50
2587	S	CF	100
2069	S	Non-CF	100
CF	S	CF	25
2524	R	CF	25
2648	R	CF	25
3022	R	Non-CF	50
5175	R	CF	25
CIP104536	R	Non-CF	25
M. massiliense			
CIP108297	R	Addison Disease	50
210	R	CF	100
179	R	CF	100
CIP108297	S	Addison Disease	100
140	S	CF	50
185	S	CF	100
107	S	CF	50
122	S	CF	100
120	S	CF	6.25
212	S	CF	100
100	S	CF	100
111	S	CF	100
M. bolletii			
CIP108541	S	Non reported	100
114	S	CF	100
17	S	CF	50
116	S	CF	100
97	S	CF	100
112	R	CF	100
19	R	Non-CF	50
10	R	Non reported	100
108	R	CF	25

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

747 **Table 3. Characterisitics of spontaneous RFB-resistant mutants of *M. abscessus*.** MIC (µg/mL) were
748 determined in Cation-adjusted Mueller-Hinton broth. Resistant strains were derived from the rough
749 *M. abscessus* CIP104536^T parental strain on Middlbrook 7H10 supplemented with either 25 or 50
750 µg/mL RFB. Single nucleotide polymorphism identification in *rpoB* (*MAB_3869c)* and corresponding
751 amino acid changes are also indicated. RFB, rifabutin.
752

753

	MIC (µg/ml)	Mutation in *rpoB*	
		SNP	AA change
CIP104536^T (R)	12.5	-	-
25.1	50	C1339T	H447Y
25.2	100	C1339G	H447D
50.1	50	C1339T	H447Y
50.2	50	C1355T	S452L

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

754 **FIGURE LEGENDS**

755 **Figure 1. *In vitro* activity of rifabutin.** *M. abscessus* CIP104536^{T} S (left panel) or R (right panel) was
756 exposed either to 200, 100, 50, 25, 12.5 or 6.25 µg/mL RFB or 16 µg/mL IPM in CaMHB at 30°C. At
757 various time points, bacteria were plated on LB agar and further incubated at 30°C for 4 days prior to
758 CFU counting. Results are expressed as the mean of triplicates ± SD and are representative of two
759 independent experiments. *$P \leq 0.05$, ** $P \leq 0.01$.

760

761 **Figure 2. Intracellular activity of RFB on *M. abscessus*-infected THP-1 cells**. **(A)** Macrophages were
762 infected with *M. abscessus* S-morphotype and **(B)** R-morphotype expressing tdTomato (MOI of 2:1)
763 for 3 hrs prior to treatment with RIF (50 µg/mL), AMK (50 µg/mL), RFB (12.5 µg/mL) or DMSO. CFU
764 were determined at 0, 1 and 3 dpi. Data are mean values ± SD for three independent experiments.
765 Data were analysed using a one-way ANOVA Kruskal-Wallis test. **(C)** Percentage of infected THP-1
766 macrophages at 0, 1 and 3 days post-infection after infection with *M. abscessus* S or **(D)** *M. abscessus*
767 R. Data are mean values ± SD for three independent experiments. Data were analysed using a one-
768 way ANOVA Kruskal-Wallis test. **(E)** Percentage of S-infected macrophage categories and **(F)**
769 percentage of R-infected macrophage categories infected with different numbers of bacilli (<5 bacilli;
770 5-10 bacilli and >10 bacilli). The categories were counted at 0 or at 1 and 3 days post-infection in the
771 absence of antibiotics or in the presence of RIF or AMK at 50 µg/mL, or RFB at 12.5 µg/mL. Values are
772 means ± SD from three independent experiments performed in triplicate. **(G)** Four immuno-
773 fluorescent fields were taken at 1 day post-infection showing macrophages infected with *M.*
774 *abscessus* expressing Tdtomato (red). The surface and the endolysosomal system of the macrophages
775 were detected using anti-CD63 antibodies (green). The nuclei were stained with DAPI (blue). White
776 arrows indicate individual or aggregate mycobacteria. Scale bar, 20 µm. ** $P \leq 0.01$, *** $P \leq 0.001$.

777

778 **Figure 3. Intracellular activity of RFB on S and R clinical isolates.** CFU counts of clinical isolates
779 exposed to 25 and 12.5 µg/mL RFB. Macrophages were infected with *M. abscessus* **(A-B)** *M. bolletii*
780 **(C-D)** or *M. massiliense* **(E-G)** clinical strains belonging to S or R morphotypes at MOI of 2:1 for 3 hrs
781 prior to treatment with 250 µg/mL AMK for 2 hrs to kill extracellular bacteria. Following extensive
782 PBS washes, cells were exposed to 50 µg/mL RIF, 50 µg/mL AMK, 25 or 12.5 µg/mL RFB . CFU were

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

783 determined at 0, 1 and 3 days post-infection. Data are mean values ± SD for two independent
784 experiments. Data were analysed using the *t*-test. *$P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$.
785
786 **Figure 4. Activity of RFB on extracellular and intracellular cords. (A)** Total number of cords
787 displayed in 20 fields at 3 days post-infection after infection of macrophages with *M. abscessus* R
788 variant. Data are mean values ± SD for three independent experiments performed in triplicate. Data
789 were analysed using one tailed Mann Whitney's *t*-test. **(B)** Percentage of cords formed either
790 extracellularly or intracellularly. The two categories were counted at 3 days post-infection in the
791 absence of antibiotics or in the presence of 50 µg/mL RIF, 50 µg/mL AMK or 12.5 µg/mL RFB.
792 Extracellular or intracellular cords are highlighted using the indicated colour codes. Values are means
793 ± SD for two independent experiments performed each time in triplicate. **(C)** Four immuno-
794 fluorescent fields were taken at 3 days post-infection showing the cords formed extracellularly or
795 within macrophages infected with *M. abscessus* R variant expressing Tdtomato (red). Macrophages
796 were infected for 3 days in the presence of DMSO, RIF (50 µg/mL), AMK (50 µg/mL) or RFB (12.5
797 µg/mL). The macrophage surface was stained using anti-CD63 antibodies (green). The nuclei were
798 stained with DAPI (blue). White arrows indicate intracellular cords, while red arrows indicate
799 extracellular cords. Scale bars represent 20 µm. Results represent the average of a total of 120 fields
800 per condition. **** $P \leq 0.0001$.
801
802 **Figure 5. RFB displays high bactericidal activity against *M. abscessus* in an embryonic zebrafish
803 infection model. (A)** Groups of uninfected embryos were immersed in water containing increasing
804 concentrations of RFB (ranging from 3.125 to 250 µg/mL) for 4 days. The red bar indicates the
805 duration of treatment. The graph shows the survival of the RFB-treated and untreated (DMSO)
806 embryos over a 12-days period. **(B)** Zebrafish embryos at 30 hrs post-fertilisation were intravenously
807 infected with approximately 250-300 CFU of *M. abscessus* CIP104536^T (R variant) expressing
808 tdTomato (n=20-25). A standard PBS injection control was included for each experiment. At 1 dpi,
809 embryos were randomly split into equal groups of approximately 20 embryos per group, and varying
810 concentrations of RFB (5 to 50 µg/mL) were added to the water. DMSO was included as a positive
811 control group. RFB was changed daily after which, embryos were washed twice in fresh embryo
812 water, maintained in embryo water and monitored daily over a 12-days period. Each treatment group

AAC Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

813 was compared against the untreated infected group with significant differences calculated using the
814 log-rank (Mantel-Cox) statistical test for survival curves. Data shown is the merge of three
815 independent experiments **(C)** Bacterial burden was determined at 2, 4 and 6 days post-infection
816 following treatment with either DMSO or 50 µg/mL RFB. Bacteria were quantified by fluorescent
817 pixel count determination using ImageJ software, with each data point representing a single embryo.
818 Error bars represent standard deviations. Statistical significance was determined by Student's *t*-test.
819 The plots represent a pool of 2 independent experiments containing approximately 20-25 embryos
820 per group. **(D)** Representative embryos from the untreated group (WT) (upper panel) and from the
821 treated group with 50 µg/mL RFB at 6 days post-infection. White arrowheads show tdTomato-
822 expressing bacteria. Scale bars represent 1 mm. $*P \leq 0.05$, $***\ P \leq 0.001$, $****\ P \leq 0.0001$.
823
824 **Figure 6. RFB reduces the pathophysiological traits of *M. abscessus* infection in zebrafish embryos.**
825 **(A)** Proportion of embryos with cords at 2 and 4 days post-infection in infected embryos that were
826 either untreated or treated with 50 µg/mL RFB (250-300 CFU, n=30). Data were analysed using an
827 unpaired student's *t*-test. Data shown is the mean of three independent experiments ± SD. **(B)** Total
828 percentage of embryos with abscesses at 4 and 6 dpi in infected embryos that were either untreated
829 or treated with 50 µg/mL RFB (250-300 CFU, n=30). Data were analysed using an unpaired student's
830 *t*-test. Data shown is the mean of three independent experiments ± SD. **(C-D)** Representative
831 zebrafish images of untreated (WT) embryos and those treated with treated with 50 µg/mL RFB at 6
832 dpi. Scale bar represents 0.5 mm. White arrows indicate extracellular cords. The white box highlights
833 a large extracellular cord based on the size and morphology, with the scale bar representing 100 µm.
834 Red overlay represents *M. abscessus* expressing tdTomato. $*P \leq 0.05$.

Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy



Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy



Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont



Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy

Accepted Manuscript Posted Online



Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy
Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

AAC

Antimicrobial Agents and Chemotherapy



Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont

Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
Antimicrobial Agents and Chemotherapy



Downloaded from http://aac.asm.org/ on August 22, 2020 at Dana Medical Library, University of Vermont